Psychedelic clinical trials face unique methodological challenges in randomization, blinding, and control that require more stringent standards than typical psychotropic trials. Randomization is compromised when participants self-select based on interest in psychedelic experiences rather than clinical need; solutions include recruiting from clinical populations with documented diagnoses and excluding those with prior psychedelic use. Blinding is difficult because psychedelics produce noticeable physiological and psychological changes; active controls with similar effects but without therapeutic benefits, such as microdosing or subtherapeutic doses of other psychotropics, are recommended. Control is complicated by combining psychedelics with psychotherapy in nonclinical settings; a factorial design with additional arms for active control plus psychotherapy and active intervention plus placebo psychotherapy is proposed.
The author argues that societal attitudes toward psychedelics, like many other beliefs, follow a pendulum-like swing between acceptance and rejection driven more by cultural forces than by evidence. Historically, psychedelics were used under strict rules, became popular in the 1960s counterculture, then were demonized due to high-profile incidents. Today, a resurgence of interest is supported by both data and a cultural shift toward acceptance. The author, a clinician, expresses concern that current clinical trials on psilocybin and LSD, when stripped of the substance's name, would likely not be published in top medical journals, suggesting the evidence is weak. The article warns that hype and rapid momentum risk destabilizing a fragile body of knowledge.